SunWay Biotech Co

SunWay Biotech Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of SunWay Biotech Co (1271.TWO) as of Oct 20, 2026 is 2.33 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 3.72 % — a change of -37.22% (lower).

EBIT/Assets

2.33 %

YoY

-37.22%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of SunWay Biotech Co is 2025 2.33 % . Operating Income to Assets Ratio (EBIT/Assets) of SunWay Biotech Co was 2024 3.72 % . It decreases by -37.22% lower compared to the previous year.

The SunWay Biotech Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2019
13.26 TWD
Jan 1, 2020
24.63 TWD
Jan 1, 2021
27.60 TWD
Jan 1, 2022
8.20 TWD
Jan 1, 2023
1.43 TWD
Jan 1, 2024
3.72 TWD
Jan 1, 2025
2.33 TWD
The SunWay Biotech Co EBIT/Assets history
YEAREBIT/AssetsYoY
2.33 %-37.22%
3.72 %+159.14%
1.43 %-82.51%
8.20 %-70.28%
27.60 %+12.07%
24.63 %+85.70%
13.26 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SunWay Biotech Co Stock analysis

What does SunWay Biotech Co do? SunWay Biotech Co., Ltd. generates revenue through the research, development, manufacture, and sale of red yeast health food products. The company's main products include Lactobacillus paracasei subsp. paracasei NTU 101 and Monascus purpureus NTU 568, which target digestive health, bacterial ecology regulation, immunity, and allergy management. These products are sold in both domestic and overseas markets, catering to consumers seeking natural health solutions. The firm focuses on health food segments where digestive and immune support are key consumer needs. The company's product portfolio emphasizes specific strains like Lactobacillus paracasei subsp. paracasei NTU 101 and Monascus purpureus NTU 568, which are marketed for their functional benefits in digestion and immune regulation. These health foods are distributed across domestic and international channels, targeting health-conscious consumers who prioritize natural remedies. SunWay Biotech leverages its research-driven approach to position these products in the health food market. SunWay Biotech Co., Ltd. operates within the health food industry, focusing on products that address digestive and immune health through natural ingredients. Its offerings are designed to improve bacterial ecology in the digestive tract and regulate immunity and allergies, appealing to a segment of consumers interested in preventive health solutions. The company's domestic and overseas market strategy ensures broad reach for its specialized health food products. SunWay Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SunWay Biotech Co stock

Operating Income to Assets Ratio (EBIT/Assets) of SunWay Biotech Co is 2.33 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of SunWay Biotech Co changed from 3.72 % to 2.33 %, representing a -37.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) SunWay Biotech Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s SunWay Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — SunWay Biotech Co

All Key Metrics — SunWay Biotech Co